<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338985</url>
  </required_header>
  <id_info>
    <org_study_id>PA17002</org_study_id>
    <nct_id>NCT03338985</nct_id>
  </id_info>
  <brief_title>Role of Senescence in the Development of Endometrial Cancer</brief_title>
  <official_title>Role of Senescence in the Development of Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several molecular studies showed chromosomal alterations in patients with endometrial cancer,
      with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of
      interest have been identified (P53, PTEN, PIK3CA, ÃŸ-catenin, K-ras ...).

      A study has already been carried out at the Reims University Hospital with inclusion of
      patients with endometrial cancer and patients with endometrial hyperplasia. It identified
      specific alterations of nosologic continuum of pathology and characterize areas of interest
      on the genome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      make a pangenomic investigation of genetic abnormalities in atypical endometrial hyperplasia
      and endometrial cancers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">April 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic imbalances</measure>
    <time_frame>Day 0</time_frame>
    <description>Genetic aberrations detected by comparative genomic hybridization (CGH arry)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Endometrial Hyperplasia and Endometrial Cancers</condition>
  <arm_group>
    <arm_group_label>Group &quot;cases patients&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with endometrial hyperplasia or endometrial cancers</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <description>Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.</description>
    <arm_group_label>Group &quot;cases patients&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with endometrial hyperplasia or endometrial cancer

          -  patient consenting to participate to the study

          -  patient enrolled in the national healthcare insurance program

          -  patient older than 18 years

        Exclusion Criteria:

        - patient with neoadjuvant chemotherapy or radiotherapy prior to surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie RAIMOND</last_name>
    <phone>0326789598</phone>
    <email>eraimond@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie RAIMOND</last_name>
      <email>eraimond@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

